The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data.
 
Karen Kelly
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - ARIAD; ARIAD; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; G1 Therapeutics; Genentech/Roche; Lilly; Lilly; Synta
Research Funding - Abbvie (Inst); Celgene (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Transgene (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Roche
 
Jeffrey R. Infante
Research Funding - Aileron Therapeutics (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Calithera Biosciences (Inst); Celldex (Inst); Celldex (Inst); eFFECTOR Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Janssen Oncology (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche (Inst); Roche (Inst); Tesaro (Inst)
 
Matthew H. Taylor
Consulting or Advisory Role - Eisai
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celldex; Eisai; Merck KGaA; Novartis
 
Manish R. Patel
No Relationships to Disclose
 
Michael S. Gordon
Stock and Other Ownership Interests - Caremission; WCCT Global
Consulting or Advisory Role - Castle Biosciences; Deciphera; RedHill Biopharma
Research Funding - Abbvie (Inst); Amgen (Inst); Amgen (Inst); Array BioPharma (Inst); Calithera Biosciences (Inst); Celldex (Inst); Deciphera (Inst); Endocyte (Inst); ESSA (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Lilly/ImClone (Inst); MedImmune (Inst); Merck Serono (Inst); Millennium (Inst); OncoMed (Inst); Pfizer (Inst); Plexxikon (Inst); Seagen (Inst); Sirtex Medical (Inst); Tokai Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Deborah Jean Lee Wong
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca/MedImmune; BioMed Valley Discoveries; Kura Oncology; Merck Serono; Merck Sharp & Dohme
 
Nicholas Iannotti
No Relationships to Disclose
 
Janice M. Mehnert
Honoraria - EMD Serono; Genentech
Consulting or Advisory Role - Amgen; Merck Sharp & Dohme
Research Funding - Amgen (Inst); AstraZeneca (Inst); Immunocore (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - EMD Serono; Merck Sharp & Dohme
Other Relationship - Amgen; EMD Serono; Merck; Merck
 
Anja Loos
Employment - Merck KGaA
Patents, Royalties, Other Intellectual Property - Merck KGaA
 
Helga Koch
Employment - EMD Serono; Merck KGaA
 
Isabell Speit
Employment - Merck KGaA
 
James L. Gulley
Consulting or Advisory Role - Prime Oncology; TRM Oncology
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); Celgene (Inst); EMD Serono (Inst)
Travel, Accommodations, Expenses - Prime Oncology; TRM Oncology